Jun 10, 2020 / NTS GMT
Andrew Scott -
Redx Pharma's Andrew Saunders is with me today. Andrew, good to see you. How are you?
Andrew Saunders -
I'm very good. Thank you. How are you?
Andrew Scott -
I'm doing well. Thanks, Andrew.
Questions and Answers:
Andrew Scott -Could you recap for us your lead clinical program, RXC004? What's that program about?
Andrew Saunders -
So RXC004 is a small molecule that inhibits the porcupine on the Wnt pathway, which is an important enzyme on the Wnt pathway. The Wnt pathway is very important in tumor growth, both inhibiting tumor growth and in causing immune evasion. So by targeting the Wnt pathway with our porcupine inhibitor, we hope to, of course, cause tumor shrinkage and clinical benefits.
Andrew Scott -
It's currently in Phase I, is it?
Andrew Saunders -
Yes. So we've gone through and are going through a classic dose escalation. We've completed 2 dose escalation cohorts, and we
Trustpilot
